The company conducts immuno-oncology and stem cell clinical trials in China using products from its integrated GMP laboratory.

In September 2018, Cellular Biomedicine entered into a strategic licensing and collaboration agreement with Swiss pharma giant Novartis to manufacture and supply the CAR-T cell therapy Kymriah (tisagenlecleucel) in China. Novartis will be the exclusive holder of the marketing license.